Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market

Table of Contents

• EXECUTIVE SUMMARY
  • Market Overview
    • Introduction and Presentation
• MONOCLONAL ANTIBODIES - OVERVIEW
  • Therapeutic Mabs
    • Overview
    • Technology Trends
  • Acronyms
    • Acronyms
• CHALLENGES AFFECTING THE THERAPEUTIC MONOCLONAL ANTIBODIES MARKET
  • Identification of the Challenges Facing the European Therapeutic Monoclonal Antibodies Market
    • Total Market Challenges
• STRATEGIC ASSESSMENT OF THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET
  • Market Engineeing Strategic Recommendations
    • Formation of Alliances between Biotech and Pharma
    • Technology Development
    • Pharmacoeconomic Analysis
    • Comparative Studies
    • End Points and License Indications
    • Manufacturing Strategies
    • Product Differentiation
    • Patient Advocacy
• RESEARCH AND DEVELOPMENT
  • Overview of the Current Situation
    • R and D: Autoimmune and Inflammatory Disease
    • R and D: Organ Transplant
    • R and D: Cardiovascular Disorders
    • R and D: Infectious Disease
  • Key Companies and Research and Marketing Collaborations
    • Overview
    • Abgenix
    • Abgenix and Sangstat
    • Alexion and Proctor & Gamble
    • CAT and Abbott
    • Celltech and Biogen
    • Celltech and Pharmacia
    • Centecor and Eli Lilly
    • Elan and Biogen
    • Genentech Xoma and Serono
    • Genmab
    • IDEC Pharmaceuticals
    • Medarex
    • Medimmune
    • Millennium
    • Novartis
    • Roche and PDL
    • Serono and Genentech
    • Schering Plough
  • Recent Research Collaborations
    • Abbott and Medarex
    • Chugai and Abgenix
    • MorphoSys and Boehringer Ingelheim
  • Overview of Products in Late Stage Development for Autoimmune Disease
    • Elan/Biogen: Antegren
    • Celltech/Pharmacia: CDP 870
    • CAT/Abbott: Humara
    • Celltech/Biogen: Humicade
    • ILEX Oncology: CAMPATH
    • Medimmune/Biotransplant: Siplizumab (MEDI-507)
    • Protein Design Labs/Roche: Daclizumab
    • Roche: MabThera (Rituximab)
    • Alexion: Eculizumab
    • Genentech/Xoma: Raptiva
    • Genentech/Novartis/Tanox: Xolair
    • Genmab/Amgen: HuMax IL15
    • Genmab: HuMax CD4
  • Overview of Products in Late Stage Development for Organ Transplant
    • Abgenix/Sangstat: ABX-CBL - Discontinued
    • Protein Design Labs: Nuvion
    • Roche: Zenapax
  • Overview of Products in Development (Other Disease Areas)
    • Alexion/P&G: Pexelizumab
    • Eli Lilly: Reopro
• MARKET ENGINEERING RESEARCH FOR THE TOTAL EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET
  • Market Overview
    • Market Challenges
    • R and D Focus
    • Potential Treatable Population - Assumptions
    • Forecasting Assumptions
    • Predicted Launches - Assumptions
  • Market Forecasts
    • Market Engineering Research Measurement System
    • Market Drivers
    • Market Restraints
    • Market Engineering Revenue Forecasts
    • Revenue Trends by Segment
    • Pricing & Reimbursement Issues
  • Competitive Analysis
    • Competitive Situation
• MARKET ENGINEERING RESEARCH FOR THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET FOR USE IN AUTOIMMUNE AND INFLAMMATORY DISEASE
  • Disease and Treatment Overview
    • Market Overview
    • Psoriasis
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Crohn's Disease
    • Asthma/Allergy
  • Epidemiology and Potential Treatable Population
    • Psoriasis
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Crohn's Disease
    • Asthma
  • Country Specific Issues
    • United Kingdom
    • France
  • Market Forecasts
    • Market Engineering Research Measurement System
    • Market Drivers
    • Market Restraints
    • Overview of Marketed Mabs
    • Market Potential by Disease
    • Forecasts for the Total Market
  • Major Product Forecasts
    • Antegren Market Forecast
    • Remicade Revenue Forecasts
    • Humara Revenue Forecasts
    • CDP 870 Revenue Forecasts
    • Raptiva Revenue Forecasts
    • Xolair Revenue Forecasts
  • Competitive Analysis
    • Future Competitive Situation
    • Overview of Competitive Products in RA
    • Overview of Competitive Products in MS
    • Overview of Competitive Products in Psoriasis
• MARKET ENGINEERING RESEARCH FOR THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET FOR USE IN ORGAN TRANSPLANT
  • Market Overview
    • Summary
    • Disease and Treatment Overview
    • Epidemiology and Potential Treatable Population
  • Market Forecasts
    • Market Drivers
    • Market Restraints
    • Overview of Marketed Monoclonal Antibodies
    • Pricing
    • Market Potential
    • Forecasting Assumptions
    • Total Revenue Forecasts
  • Product Trends and Uptake
    • Simulect
    • Zenapax
    • Nuvion
  • Competitive Anaylsis
    • Competitive Situation
    • Overview of Competitive Products
• OVERVIEW OF THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET FOR USE IN CARDIOVASCULAR DISORDERS
  • Overview
    • Introduction to Cardiovascular Disease
    • Cardiovascular Disease Areas of Interest
    • Epidemiology
  • Current and Future Market Situation
    • Market Drivers and Restraints
    • Overview of Reopro
    • Research & Development Activities
    • Reopro Market Potential and Forecast
    • Pexelizumab Market Potential and Forecast
  • Competitive Situation
    • Future Competitive Environment
• OVERVIEW OF THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET FOR USE IN INFECTIOUS DISEASE
  • Market Overview
    • Introduction
    • Respiratory Syncticial Virus - Overview and Treatment
    • Potential Treatable Population in RSV
  • Current & Future Market Situation
    • Market Opportunities and Challenges
    • Overview of Synagis
    • Cost-Benefit Analysis of Synagis
    • Research and Development Activities
    • Synagis Market Potential and Revenue Forecast
• MARKET ENGINEERING AWARDS FOR THE EUROPEAN THERAPEUTIC MONOCLONAL ANTIBODIES MARKET
  • Market Engineering Awards
    • Market Engineering Awards 2003
    • Product Innovation Award